The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical discussed areas of multiple sclerosis research that need more attention.
Luc Truyen, MD, PhD
Advertisement
Chief medical officer, argenx
Articles by Luc Truyen, MD, PhD
The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical detailed the areas research has grown in MS and areas that still need more examination.
The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical detailed what makes ponesimod different from other currently FDA-approved treatments.
The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical discussed the results of a phase 2 core and extension study of ponesimod in patients with relapsing-remitting multiple sclerosis.
Advertisement
Latest Updated Articles
Luc Truyen, MD, PhD: Advantages of Ponesimod as an S1P ModulatorPublished: September 22nd 2020 | Updated:
Luc Truyen, MD, PhD: Long-Term Results of Ponesimod in Phase 2b StudyPublished: September 18th 2020 | Updated:
Unmet Needs in the Multiple Sclerosis Community: Luc Truyen, MD, PhDPublished: March 1st 2021 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Parkinson Agent Tavapadon Shows Continued Efficacy, Safety in Phase 3 TEMPO-4 Trial
2
NeurologyLive® Brain Games: October 19, 2025
3
Bilateral MR-Guided Focused Ultrasound Shows Benefit for Managing Parkinson Motor Complications in Phase 3 Trial
4
Ruptured vs Unruptured Aneurysms: Practical Decision Making with Guilherme Dabus, MD
5
